Menopausal syndrome

WHI ran the estrogen plus progestin trial, which proved that a common hormone therapy used to treat menopause increased the risk of coronary heart disease and breast cancer.\n The Department of Health and Human Services (HHS) is cutting off funding to the long-running Women’s Health Initiative (WHI) in September, a move that leaves the fate of one of the world\'s largest women’s health studies hanging in the balance.The agency is canceling contracts to the WHI’s regional centers by the end of September, the WHI said in an April 21 announcement. The initiatives’ coordinating center, housed at the Fred Hutchinson Cancer Center in Seattle, will continue running until January 2026, after which “its funding remains uncertain,” according to the announcement.At the time of publication, the HHS and Fred Hutchinson Cancer Center had not responded to Fierce\'s request for comment.WHI regional centers are spread across the country at locations in New York, Massachusetts, Ohio, North Carolina, California and Washington.The original WHI study began in 1991 with funding from the NIH’s National Heart, Lung and Blood Institute. The study enrolled 161,808 women between the ages of 50 and 79, investigating strategies to prevent heart disease, osteoporosis and breast and colorectal cancer.After the initial study wrapped in 2005, the initiative has continued through multiple extension studies that follow original study participants, with more than 42,000 women still involved. Scientists associated with WHI have published more than 2,400 scientific papers and tracked tens of thousands of cancer cases, cardiovascular events and deaths, according to the recent announcement. One of WHI’s signature discoveries came from the estrogen plus progestin trial, which proved that a common hormone therapy used to treat menopause can increase the risk of coronary heart disease and breast cancer. The evidence of the therapy’s dangers was so strong that the trial was halted three years early. The WHI says the release of the findings prevented an estimated 126,000 breast cancer cases and 76,000 cardiovascular disease cases over the following decade, representing $35.2 billion saved in direct medical costs.Since then, WHI scientists have broadened their remit to a number of other age-related health issues, including frailty, vision loss, dementia, mental health and social isolation, according to the announcement.The Trump administration’s canceling of women’s health funding stands in stark contrast to that of his predecessor. Former President Biden launched a women’s health effort in November 2023, helmed by former First Lady Jill Biden, and asked Congress for $12 billion to fund research on diseases that commonly affect women like rheumatoid arthritis, menopause, Alzheimer’s disease and endometriosis. 

First-of-its-Kind Research Aims to Fill the Gap in Women's Hormonal Health NEW YORK, April 3, 2025 /PRNewswire/ -- FLO Living is leading a groundbreaking study to evaluate the impact of the Cycle Syncing® Method on menstrual cycle symptom burden (total number of symptoms) and symptom severity (intensity of those symptoms). Backed by Mira, Hello Inside, and Citruslabs, this research is a major step toward validating a dietary and lifestyle-based approach to hormonal health. Continue Reading A message from FLO Living founder and Cycle Syncing® Creator Alisa Vitti The first official Cycle Syncing® Study "We're living in historic times for women's health," says Alisa Vitti, founder of FLO Living. "With the rise of femtech solutions, women have more control over their hormonal health than ever before. Our partnership with Mira, Hello Inside, and Citruslabs demonstrates how the femtech community can work together to push research forward. Most importantly, it lays the foundation for a new standard of care that integrates dietary and lifestyle interventions with pharmaceutical options—helping women receive more holistic, research-backed support." The Cycle Syncing® Method, first introduced in Vitti's book In the FLO (HarperCollins, 2020), aligns nutrition, exercise, and lifestyle choices with the four phases of the menstrual cycle. By adjusting calorie intake, food type, workout intensity, and other daily habits, the method aims to support blood sugar, cortisol, and progesterone levels—helping to reduce hormonal symptoms throughout the month. Addressing a Critical Gap in Women's Health Women's health research remains critically underfunded, and menstrual health is still widely misunderstood. This study aims to change that by providing gynecologists and healthcare professionals with evidence-backed confidence in a practical, non-pharmaceutical approach that can be used between annual visits. "Women's health remains one of the most underserved areas in scientific research, and the menstrual cycle is still largely misunderstood," says Susanne Mitschke, Co-Founder & CEO of Citruslabs. "This collaboration marks a historic step toward closing that gap. At Citruslabs, we're honored to be part of this initiative—validating Cycle Syncing® through robust clinical evidence and championing a new era of research that finally centers on women's lived experiences." At the heart of the study is real-time data tracking to measure how the Cycle Syncing® Method influences blood glucose levels, hormone patterns, and menstrual symptoms. By leveraging Hello Inside's metabolic health insights, Mira's hormone tracking expertise, and Citruslabs' research capabilities, the study will offer clinical validation for a lifestyle-driven approach to hormone health. "We are thrilled to be at the forefront of advancing women's health research alongside the brilliant teams at FLO Living and Mira Health," says Mario Aichlseder, CEO & Founder of Hello Inside. "By combining their expertise in menstrual health and fertility with Hello Inside's metabolic health insights, we are uncovering invaluable data on how women's bodies function at all life stages. This partnership is unlocking the powerful signals of the female body, giving women deeper insights into their health and empowering them to take control." "At Mira, we believe data is power—especially in women's health," says Sylvia Kang, CEO & Founder of Mira. "This study is a critical step toward understanding how Cycle Syncing® affects hormone levels, symptom severity, and metabolic health. If successful, this research could provide doctors with a trusted, non-invasive way to help women manage PMS, cramps, and heavy bleeding—while also setting a new standard for gender-specific health research." This study marks a turning point in women's daily hormonal care—filling in research gaps and laying the foundation for more personalized, proactive support. With a united effort from industry-leading femtech companies and a growing community of empowered participants, the future of hormone health looks brighter than ever. Click here to participate in the study. For all media inquiries, contact [email protected] / [email protected]. About FLO Living FLO Living is a digital-first hormone health company founded by Alisa Vitti, author of WomanCode and In the FLO. The company is on a mission to help women eliminate period problems, balance their hormones naturally, and optimize their health through every life stage. Through proprietary programs, supplements, and the MyFLO® app, FLO Living delivers personalized, phase-based hormonal support rooted in the Cycle Syncing® Method. About Mira Mira is a San Francisco-based hormonal health company providing integrative care and hormonal testing for over 130,000 customers. Mira was founded in late 2015 by a group of scientists, engineers, OBGYN doctors, and business execs to solve the problem of the unavailability of advanced home health testing. The company's mission is to develop data-driven hormonal health solutions to help women make confident health decisions during every stage of their lives – from the menstrual stage to menopause. About Hello Inside Hello Inside is a science-driven health company helping women make smarter, more personalized choices through real-time glucose tracking. By combining continuous glucose monitoring (CGM) with holistic metabolic health insights and nutrition consultations, Hello Inside helps users understand their own body and its response to diet, exercise, sleep and stress. In-app educational programs specifically tailored to women's needs transform daily wellness into actionable self-care, reducing hormonal imbalances, alleviating PMS symptoms and supporting health during menopause. About Citruslabs Citruslabs is a leader in accessible clinical research for health and wellness brands. Their platform connects companies with real users to conduct IRB-approved studies that generate reliable data and substantiated health claims. By making clinical research faster, more affordable, and more transparent, Citruslabs is helping build a healthier, more evidence-based future in consumer wellness. SOURCE FLO Living WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SCOTTSDALE, Ariz., April 2, 2025 /PRNewswire/ -- The Pause Technologies, a real-time AI platform dedicated to menopause support, announces the successful completion of the Mayo Clinic and Arizona State University MedTech Accelerator. Out of a global pool of applicants, only ten companies were selected for the 2025 cohort. The Pause Technologies was the only female-founded company included in this year's cohort. Continue Reading Dr. Mia Chorney, Co-Founder and CMO, and Susan Sly, Founder and CEO of The Pause Technologies. Founded with a singular mission to redefine menopause through personalized, evidence-based AI, The Pause Technologies is addressing a market often ignored by mainstream health innovation. Its proprietary platform, thePause™, delivers 24/7 real-time symptom support, biometric feedback integration, and clinical-grade insights—transforming how women navigate perimenopause and menopause. The Mayo Clinic and ASU MedTech Accelerator is one of the most selective programs globally for early-stage medical technology companies. Participants gain unparalleled access to clinical, academic, and commercial expertise to refine their solutions for real-world impact. "The current healthcare system is reactive and often excludes women's midlife health experiences entirely. Oprah's recent special on menopause has amplified what millions of women already know—that their symptoms are real, their experiences are valid, and their needs have been ignored for far too long," said Susan Sly, CEO and Founder of The Pause Technologies. "Completing this accelerator validates our mission to deliver intelligent, real-time support to women in menopause. Being the only female-founded company in this cohort underscores exactly why we are here—to build what no one else has built, for women who have waited long enough."According to Forbes, more than one billion women are expected to be in menopause globally by 2030, the demand for innovation in this space is rising. thePause™ is built to meet this moment with real-time, adaptive support that empowers women to better understand and manage their health."Menopause is still surrounded by stigma, misinformation, and a lack of proactive care," said Dr. Mia Chorney, Chief Medical Officer and Co-founder of The Pause Technologies. "Through this program, we were able to deepen our clinical validation, pressure-test our architecture with leading minds, and accelerate our strategy to bring better outcomes to more women. Our vision is a world where menopause is not a burden, but a phase of life supported by intelligent, empathetic technology."The Pause Technologies is actively scaling partnerships with enterprise healthcare systems, wellness providers, and clinical researchers to expand access and impact.To learn more about The Pause Technologies and its real-time AI platform for menopause, visit . Media Contact: Diana Frerick Director of Strategic Communications The Pause Technologies [email protected] About The Pause Technologies: The Pause Technologies is leading the next frontier of women's health with a proprietary AI platform designed to support women through perimenopause and menopause. Founded by award-winning AI entrepreneur Susan Sly, thePause™ provides intelligent, personalized, real-time support to help women navigate hormonal change with clarity and control. Headquartered in Scottsdale, Arizona, thePause™ is a woman-founded, science-backed, mission-driven company. SOURCE The Pause Technologies WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED